Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MCARH109 |
Trade Name | |
Synonyms | MCARH-109|MCARH 109 |
Drug Descriptions |
MCARH109 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting GPRC5D and CD137 (4-1BB), which may selective recognize GPRC5D expressing tumor cells and activate anti-tumor immune response (PMID: 36170501). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C176222 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
MCARH109 | MCARH109 | 0 | 1 |
MCARH109 + MCARH125 | MCARH109 MCARH125 | 0 | 1 |